Kite Pharma was off by 15% in morning trading after it announced the death of a patient in late April of cerebral edema—the very same fatal outcome that beset rival Juno’s Rocket trial, killing five ...
Kite Pharma, Inc.KITE reported wider-than-expected loss in the first quarter of 2017. Shares of the biotech company declined more than 13% on Monday after it announced the death of a cancer patient ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results